Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Recent data have transformed management strategies for patients with advanced hepatocellular carcinoma (HCC). In this activity, Richard Finn, MD, discusses contemporary treatment of these patients, with a focus on new options in the first-line systemic therapy setting and his approach to second-line therapy.
Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once prior to the discussion that informs the best choice, and then once again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.